Consolidative thoracic radiotherapy for extensive stage small cell lung cancer

Xiaoli Zhang; Jinming Yu; Hui Zhu; Xue Meng; Minghuan Li; Liyang Jiang; Xingchen Ding; Xindong Sun

doi:10.18632/oncotarget.14759

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Consolidative thoracic radiotherapy for extensive stage small cell lung cancer

Xiaoli Zhang, Jinming Yu _, Hui Zhu, Xue Meng, Minghuan Li, Liyang Jiang, Xingchen Ding and Xindong Sun

PDF | HTML | How to cite

Oncotarget. 2017; 8:22251-22261. https://doi.org/10.18632/oncotarget.14759

Metrics: PDF 4490 views | HTML 3961 views | ?

Abstract

Xiaoli Zhang1,2, Jinming Yu1,2,3, Hui Zhu2,3, Xue Meng2,3, Minghuan Li2,3, Liyang Jiang2,3, Xingchen Ding2,4 and Xindong Sun2,3

1. Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China

2. Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, Jinan, China

3. Shandong Academy of Medical Sciences, Jinan University, Jinan, China

4. Weifang Medical University, Weifang, China

Correspondence to:

Jinming Yu, email:

Keywords: small cell lung cancer, extensive stage, thoracic radiotherapy

Received: November 09, 2016 Accepted: January 11, 2017 Published: January 19, 2017

Abstract

Extensive stage small cell lung cancer (ES-SCLC) represents approximately half of all diagnosed small cell lung cancer worldwide. It is notorious for a high risk of local recurrence although it’s sensitive to chemotherapy. Nearly 90% of intrathoracic failures happen in the first year after diagnosis. The cornerstone of treatment for ES-SCLC is etoposide-platinum based chemotherapy. Consolidative radiotherapy to thorax has diminished the incidence of local relapse, therefore it should be offered to patients with excellent response to induction first-line chemotherapy. This review centers on the clinical evidence for the use of thoracic radiotherapy (TRT) and current modalities of TRT delivery, then tries to determine a feasible way to conduct TRT in a selective group of cases.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14759

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Consolidative thoracic radiotherapy for extensive stage small cell lung cancer

Abstract